The biotech firm reports a Q1 GAAP loss of $526.11 per share while holding $388.9 million in cash through March 31, 2026. BridgeBio Oncology Therapeutics reported a first-quarter GAAP loss of $526.11 per share, reflecting ongoing investment in drug development. The company
The biotech firm reports a Q1 GAAP loss of $526.11 per share while holding $388.9 million in cash through March 31, 2026. BridgeBio Oncology Therapeutics reported a first-quarter GAAP loss of $526.11 per share, reflecting ongoing investment in drug development. The company
Biotech firm AnaptysBio reports Q1 GAAP EPS of -$1.84, missing estimates, while revenue exceeds expectations by $6.69M. AnaptysBio posted a Q1 GAAP loss per share of -$1.84, wider than expected by $1.04. The company’s collaboration revenue reached $25.56M, surpassing estim
Biotech firm AnaptysBio reports Q1 GAAP EPS of -$1.84, missing estimates, while revenue exceeds expectations by $6.69M. AnaptysBio posted a Q1 GAAP loss per share of -$1.84, wider than expected by $1.04. The company’s collaboration revenue reached $25.56M, surpassing estim
The business development company reported adjusted net investment income of $0.20 per share for the quarter ending March 31, 2026. Gladstone Investment reported adjusted net investment income (NII) of $0.20 per weighted average common share for the quarter ended March 31,
The biotech firm reported a smaller-than-expected GAAP loss per share and reduced adjusted EBITDA loss for the quarter. Fractyl Health posted a first-quarter GAAP loss per share of $0.06, beating expectations by $0.11. The result reflects a narrower loss compared to estima
Intelligent Protection Management reports smaller-than-expected Q1 loss and revenue beat, with adjusted EBITDA improving year-over-year. Intelligent Protection Management posted a Q1 GAAP loss of $0.05 per share, narrower than the expected loss by $0.02. Revenue reached $6
Canadian Banc to give 10 extra shares for every 100 held Canadian Banc will complete a share split of its Class A shares. The split will give Class A shareholders on record as of May 19, 2026, 10 additional shares for every 100 shares held. Shareholders wil
Higher-than-anticipated retail inflation in April weighed on equities, overshadowing geopolitical developments. Wall Street closed mostly lower Tuesday after April’s retail inflation report exceeded expectations, dampening hopes for near-term rate cuts. The Dow eked out a
RLMD reports a GAAP loss per share of $0.22, falling short of expectations as R&D expenses decline year-over-year. Relmada Therapeutics posted a first-quarter GAAP earnings per share loss of $0.22, missing estimates by $0.02. The result reflects ongoing investment in clini